Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. The company is headquartered in Chicago, Illinois.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-3.29M |
| EBITDA | $-9.88M |
| Operating Margin | 0.00% |
| Return on Equity | -92.50% |
| Return on Assets | -43.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.62 |
| Price-to-Book | 6.25 |
| Price-to-Sales (TTM) | 13.61 |
| EV/Revenue | 27.17 |
| EV/EBITDA | -0.04 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 928.00% |
| Shares Outstanding | $6.37M |
| Float | $3.38M |
| % Insiders | 35.38% |
| % Institutions | 2.33% |
Volatility is currently contracting